In this report, we share a case of a 78-year-old patient with advanced pancreatic adenocarcinoma who refused chemotherapy due to advanced age and subsequently received low-dose dabrafenib combined with trametinib based on the presence of a BRAF V600E mutation. This evidence concerns the gene BRAF and pancreatic adenocarcinoma.